Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Register for Details

For more details on financing and valuation for Acelyrin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Acelyrin

Forge green plus iconForge green minus icon

What is Acelyrin's IPO price?

Acelyrin's IPO price is $5.97 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Acelyrin's funding to date?

Acelyrin has raised $558MM to date.
Forge green plus iconForge green minus icon

When was Acelyrin founded?

Acelyrin was founded in 2020.

Who are Acelyrin's major investors?

Cowen Group
Marshall Wace
Matrix Partners
Decheng Capital
Westlake Village BioPartners
OrbiMed Healthcare Fund Management
Samsara Biocapital
venBio
RTW Investments
Surveyor
Tybourne Capital Management

Acelyrin Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
9/9/2022 Series C $300MM raised $XXX.XX $XXX.XX
11/16/2021 Series B $250MM raised $XXX.XX $XXX.XX
12/15/2020 Series A $8MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.